Market cap
$28 Mln
Recently Viewed
Clear All$11.10
$-1.50
(-11.90%)
As on 26-Mar-2024 20:00EDT
Market cap
$28 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-6 Mln
ROE
0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-3.2
Debt to Equity
0.8
Book Value
$5.1
EPS
$-13.7
Face value
--
Shares outstanding
2,500,750
CFO
$-62.28 Mln
EBITDA
$-64.92 Mln
Net Profit
$-88.63 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
| -18.0 | -14.7 | -17.8 | -51.6 | -43.7 | -39.9 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
| -30.3 | -49.4 | -28.3 | -16.5 | -39.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
11.1 | 27.8 | 0.1 | -14.8 | -8,225.6 | 252.1 | -- | 5.1 |
| 32.5 | 3,728.2 | 31.1 | -105.4 | -315.3 | -64.2 | -- | 12.8 |
As of March 26, 2024, AgeX Therapeutics, Inc. was acquired by Serina Therapeutics, Inc., in a reverse merger transaction. AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics... targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California. Read more
Chief Financial Officer
Ms. Eun-Jae Park CPA
Chief Information Officer
Dr. Ivan Labat
Headquarters
Alameda, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of AgeX Therapeutics Inc (AGE) is $11.10 (NYSE) as of 26-Mar-2024 20:00 EDT. AgeX Therapeutics Inc (AGE) has given a return of -43.72% in the last 3 years.
Since, TTM earnings of AgeX Therapeutics Inc (AGE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.03
|
0.08
|
|
2022
|
-0.06
|
-0.03
|
|
2021
|
-4.05
|
-3.49
|
|
2020
|
-5.22
|
-11.21
|
|
2019
|
-5.53
|
30.89
|
The 52-week high and low of AgeX Therapeutics Inc (AGE) are Rs -- and Rs -- as of 30-Apr-2026.
AgeX Therapeutics Inc (AGE) has a market capitalisation of $ 28 Mln as on 26-Mar-2024. As per SEBI classification, it is a Small Cap company.
Before investing in AgeX Therapeutics Inc (AGE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.